Latest news with #ProMedicus
Yahoo
25-05-2025
- Business
- Yahoo
High Growth Tech Stocks To Watch In Australia May 2025
As the Australian market anticipates a modest 0.17% gain with the ASX 200 futures pointing upwards, investors are keeping a close eye on tech stocks amid recent global uncertainties and shifting economic dynamics. In this environment, identifying high growth tech companies that demonstrate resilience and adaptability to market fluctuations can be key for those looking to navigate potential opportunities in Australia's evolving landscape. Name Revenue Growth Earnings Growth Growth Rating Gratifii 42.14% 113.99% ★★★★★★ Pro Medicus 22.19% 23.49% ★★★★★★ BlinkLab 65.54% 64.35% ★★★★★★ WiseTech Global 20.14% 25.01% ★★★★★★ Wrkr 57.01% 116.83% ★★★★★★ AVA Risk Group 29.15% 108.15% ★★★★★★ Immutep 70.42% 42.39% ★★★★★☆ Echo IQ 61.50% 65.86% ★★★★★★ Pointerra 50.42% 159.12% ★★★★★☆ SiteMinder 19.93% 69.52% ★★★★★☆ Click here to see the full list of 49 stocks from our ASX High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Audinate Group Limited specializes in developing and selling digital audio visual networking solutions both in Australia and internationally, with a market cap of A$621.01 million. Operations: The company generates revenue primarily through its Contract Electronics Manufacturing Services, amounting to A$73.60 million. Audinate Group, despite recent challenges including its drop from the S&P/ASX 200 Index, exhibits promising growth metrics. With an annual revenue increase of 16.2%, surpassing the Australian market's average of 5.6%, and a projected earnings surge of 50.3% per year, AD8 is outpacing general market expectations significantly. However, it's crucial to note that its profit margins have declined from last year's 18.5% to just 4.5%. This financial juxtaposition highlights a volatile yet potentially rewarding trajectory for investors focused on tech innovation and market resilience in Australia's high-tech sector. Click to explore a detailed breakdown of our findings in Audinate Group's health report. Gain insights into Audinate Group's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Data#3 Limited is an IT solutions and services provider operating in Australia, Fiji, and the Pacific Islands with a market capitalization of A$1.17 billion. Operations: The company generates revenue primarily through its role as a value-added IT reseller and solutions provider, with this segment contributing A$798.05 million. The business focuses on delivering comprehensive IT services across Australia, Fiji, and the Pacific Islands. Data#3 Limited, amidst a dynamic IT landscape, is demonstrating robust growth with a notable annual revenue increase of 24.4%, significantly outpacing the Australian market average of 5.6%. Despite this surge, its earnings growth at 10.5% per year trails the broader market forecast of 11.8%. The company's strategic focus on innovation is evident from its substantial R&D investment, aligning with industry shifts towards more integrated tech solutions. Recent board changes could signal a fresh perspective to propel future strategies, though insider selling raises cautions about potential undercurrents within its corporate governance structure. Take a closer look at Data#3's potential here in our health report. Review our historical performance report to gain insights into Data#3's's past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for life, accident, and health insurers as well as employee benefits providers across North America, the Asia Pacific, the Middle East, and Africa with a market cap of A$842.91 million. Operations: FINEOS Corporation Holdings generates revenue primarily from its software and programming segment, amounting to €133.22 million. The company focuses on providing enterprise solutions for claims and policy management tailored to the needs of insurers and benefits providers across various regions including North America, Asia Pacific, the Middle East, and Africa. FINEOS Corporation Holdings is navigating a transformative phase, underscored by strategic alliances and robust guidance for fiscal 2025. The company's recent partnership with Wellthy aims to revolutionize care management through advanced integration and automation, enhancing operational efficiency and broadening service offerings beyond traditional insurance benefits. This collaboration aligns with the increasing demand for holistic, personalized healthcare solutions, potentially accelerating FINEOS' market presence and customer satisfaction. Moreover, the firm has reaffirmed its revenue forecast between €138 million to €143 million for FY25, reflecting confidence in its growth trajectory despite reporting a net loss of €5.8 million in FY24. These initiatives could position FINEOS as a pivotal player in reshaping health benefits administration through technology-driven solutions. Click here and access our complete health analysis report to understand the dynamics of FINEOS Corporation Holdings. Gain insights into FINEOS Corporation Holdings' past trends and performance with our Past report. Unlock more gems! Our ASX High Growth Tech and AI Stocks screener has unearthed 46 more companies for you to here to unveil our expertly curated list of 49 ASX High Growth Tech and AI Stocks. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AD8 ASX:DTL and ASX:FCL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
25-05-2025
- Business
- Yahoo
High Growth Tech Stocks To Watch In Australia May 2025
As the Australian market anticipates a modest 0.17% gain with the ASX 200 futures pointing upwards, investors are keeping a close eye on tech stocks amid recent global uncertainties and shifting economic dynamics. In this environment, identifying high growth tech companies that demonstrate resilience and adaptability to market fluctuations can be key for those looking to navigate potential opportunities in Australia's evolving landscape. Name Revenue Growth Earnings Growth Growth Rating Gratifii 42.14% 113.99% ★★★★★★ Pro Medicus 22.19% 23.49% ★★★★★★ BlinkLab 65.54% 64.35% ★★★★★★ WiseTech Global 20.14% 25.01% ★★★★★★ Wrkr 57.01% 116.83% ★★★★★★ AVA Risk Group 29.15% 108.15% ★★★★★★ Immutep 70.42% 42.39% ★★★★★☆ Echo IQ 61.50% 65.86% ★★★★★★ Pointerra 50.42% 159.12% ★★★★★☆ SiteMinder 19.93% 69.52% ★★★★★☆ Click here to see the full list of 49 stocks from our ASX High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Audinate Group Limited specializes in developing and selling digital audio visual networking solutions both in Australia and internationally, with a market cap of A$621.01 million. Operations: The company generates revenue primarily through its Contract Electronics Manufacturing Services, amounting to A$73.60 million. Audinate Group, despite recent challenges including its drop from the S&P/ASX 200 Index, exhibits promising growth metrics. With an annual revenue increase of 16.2%, surpassing the Australian market's average of 5.6%, and a projected earnings surge of 50.3% per year, AD8 is outpacing general market expectations significantly. However, it's crucial to note that its profit margins have declined from last year's 18.5% to just 4.5%. This financial juxtaposition highlights a volatile yet potentially rewarding trajectory for investors focused on tech innovation and market resilience in Australia's high-tech sector. Click to explore a detailed breakdown of our findings in Audinate Group's health report. Gain insights into Audinate Group's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Data#3 Limited is an IT solutions and services provider operating in Australia, Fiji, and the Pacific Islands with a market capitalization of A$1.17 billion. Operations: The company generates revenue primarily through its role as a value-added IT reseller and solutions provider, with this segment contributing A$798.05 million. The business focuses on delivering comprehensive IT services across Australia, Fiji, and the Pacific Islands. Data#3 Limited, amidst a dynamic IT landscape, is demonstrating robust growth with a notable annual revenue increase of 24.4%, significantly outpacing the Australian market average of 5.6%. Despite this surge, its earnings growth at 10.5% per year trails the broader market forecast of 11.8%. The company's strategic focus on innovation is evident from its substantial R&D investment, aligning with industry shifts towards more integrated tech solutions. Recent board changes could signal a fresh perspective to propel future strategies, though insider selling raises cautions about potential undercurrents within its corporate governance structure. Take a closer look at Data#3's potential here in our health report. Review our historical performance report to gain insights into Data#3's's past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for life, accident, and health insurers as well as employee benefits providers across North America, the Asia Pacific, the Middle East, and Africa with a market cap of A$842.91 million. Operations: FINEOS Corporation Holdings generates revenue primarily from its software and programming segment, amounting to €133.22 million. The company focuses on providing enterprise solutions for claims and policy management tailored to the needs of insurers and benefits providers across various regions including North America, Asia Pacific, the Middle East, and Africa. FINEOS Corporation Holdings is navigating a transformative phase, underscored by strategic alliances and robust guidance for fiscal 2025. The company's recent partnership with Wellthy aims to revolutionize care management through advanced integration and automation, enhancing operational efficiency and broadening service offerings beyond traditional insurance benefits. This collaboration aligns with the increasing demand for holistic, personalized healthcare solutions, potentially accelerating FINEOS' market presence and customer satisfaction. Moreover, the firm has reaffirmed its revenue forecast between €138 million to €143 million for FY25, reflecting confidence in its growth trajectory despite reporting a net loss of €5.8 million in FY24. These initiatives could position FINEOS as a pivotal player in reshaping health benefits administration through technology-driven solutions. Click here and access our complete health analysis report to understand the dynamics of FINEOS Corporation Holdings. Gain insights into FINEOS Corporation Holdings' past trends and performance with our Past report. Unlock more gems! Our ASX High Growth Tech and AI Stocks screener has unearthed 46 more companies for you to here to unveil our expertly curated list of 49 ASX High Growth Tech and AI Stocks. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AD8 ASX:DTL and ASX:FCL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
News.com.au
21-05-2025
- Business
- News.com.au
ASX medtechs chasing FDA De Novo for a shot at big US markets
Nanosonics scores FDA De Novo approval in March EMVision is also targeting De Novo for its brain scanner The company's big potential in the US When Nanosonics (ASX:NAN) landed FDA De Novo clearance for its CORIS system back in March, the market took notice, and for good reason. The CORIS system is not only a world-first device designed to clean the complex inner channels of endoscopes. It also walked the De Novo path – a route the US FDA reserves for genuinely new technologies. De Novo (which literally means "from new" in Latin) is not a simple clearance. This one is for devices without a predicate – i.e. no similar product already on the market. That means the FDA has to classify and assess the technology from the ground up. In short: it's hard to get, and a big deal if you do. Investors responded in kind, with Nanosonics' share price jumping by 13% on the news that day. Other ASX medtechs are also currently chasing De Novo clearance. PainChek (ASX:PCK), for instance, is waiting on a mid-2025 decision for its pain-assessment app. TrivarX (ASX:TRI) is also pursuing the De Novo path, with a pivotal trial in the works for its mental health wearable. Just a few years earlier, in 2016, another Aussie medtech, ProMedicus (ASX:PME), also made inroads in the States, thanks to a key partnership with none other than the prestigious Mayo Clinic. Since 2016, ProMedicus shares have gone on a jaw-dropping tear, up by more than 9000% today. Filling the CT and MRI gap Now, the $145m market capped EMvision Medical Devices (ASX:EMV) is quietly walking a similar path. We're not suggesting EMvision is about to pull a Nanosonics or do a ProMedicus victory lap. But, with De Novo ambitions of its own and an eye on cracking the US, it's probably one stock worth keeping on the radar. The Brisbane-based company is in the thick of a pivotal trial at Mayo Clinic in Florida, UTHealth in Houston, as well as the Royal Melbourne in Australia. Mayo Clinic joined the trial after clinicians there reached out to the company, having come across EMVision's EMU product. EMU is a portable, bedside brain scanner that aims to help detect strokes and bleeds where access to CT and MRI is limited or simply not practical. 'It has a physical footprint similar to a cart-based ultrasound system, and it's designed to support point-of-care diagnosis for stroke and stroke-like symptoms," EMV CEO Scott Kirkland told Stockhead. The company is also currently chasing De Novo approval for the device. But if you're wondering whether this could eventually compete with CT or MRI, the answer is… not really. And that's the point. 'We're not trying to replace a CT or an MRI. In fact, we're here to fill a gap where they are not available," said Kirkland. EMU's trials and First Responder EMU isn't just a 'me-too' device – a term for products or drugs that make minor modifications from a better known prototype. It's going after stroke, one of the biggest health problems on the planet. One in four adults will suffer a stroke in their lifetime, and most don't walk away unscathed – two out of three lead to lasting disability. What makes it worse is that many patients, especially in the regions, can't get timely access to imaging. The nearest CT could be hours away. EMU is now in a pivotal trial, aiming to enrol 300 patients across six sites; three up and running, three more to come. The primary endpoint of the trials is its ability to detect the presence or absence of haemorrhage. 'We have a gold-standard reference diagnosis expert panel that assesses all the ground truths, which are then compared with our diagnostic output to determine our sensitivity and specificity. "The minimum performance criteria is to exceed 80% sensitivity and 80% specificity. That's the minimum, but there's nothing to stop us from going as high as possible." Stroke's not the only target for EMV. One of EMVision's four trials is also focused on traumatic brain injury. Then there's the First Responder. It's backpack-sized, battery-powered, and built for use in ambulances and aeromedical units, not hospital wards. The device has already been tested with the Royal Flying Doctor Service and the Australian Stroke Alliance in outback South Australia. Next up is a trial inside a Melbourne stroke ambulance, the kind with a CT scanner in the back. 'First Responder doesn't require a specialist operator, such as a radiographer, and the output can be sent back to a neurologist to guide decision making – whether that's triage, transfer or potentially treatment at the scene," Kirkland said. Mapping the US market Crucially, EMVision isn't just taking a punt on the US, it has a clear plan for where its technology belongs. Kirkland reckons there are around 10,000 EMU opportunities across US stroke wards, ICUs and EDs. 'Within our first targets, there are really two ends of the spectrum. "One is comprehensive and primary stroke centre, the other are critical access hospitals, which are small regional clinics with 25 beds or less,' he explained. The First Responder has an even bigger runway – about 60,000 units, covering both road and air ambulances. And every scan comes with a consumable (a cap and coupling media), adding recurring revenue of around US$25 per scan for EMU, and closer to US$50 for First Responder. Kirkland is clear-eyed about what comes next. 'We've guided that we expect to head to the market kind of late calendar year 2026,' he said. 'It's a very, very large market. You can do the numbers, and if we can achieve 10% of the market, it is a very large business indeed.' With De Novo ambitions, a top-shelf US trial, and the Mayo Clinic in its corner, EMVision is playing a long game. No aggressive claims, just data collection and careful steps. But in the world of medtech, careful steps in the right direction can sometimes lead to very big leaps.
Yahoo
20-05-2025
- Business
- Yahoo
Here's Why We Think Pro Medicus (ASX:PME) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Pro Medicus (ASX:PME). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. To the delight of shareholders, Pro Medicus has achieved impressive annual EPS growth of 37%, compound, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors. Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. The good news is that Pro Medicus is growing revenues, and EBIT margins improved by 5.1 percentage points to 72%, over the last year. That's great to see, on both counts. You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers. View our latest analysis for Pro Medicus You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Pro Medicus' future profits. Seeing insiders owning a large portion of the shares on issue is often a good sign. Their incentives will be aligned with the investors and there's less of a probability in a sudden sell-off that would impact the share price. So those who are interested in Pro Medicus will be delighted to know that insiders have shown their belief, holding a large proportion of the company's shares. Owning 49% of the company, insiders have plenty riding on the performance of the the share price. Shareholders and speculators should be reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. And their holding is extremely valuable at the current share price, totalling AU$14b. This is an incredible endorsement from them. It's good to see that insiders are invested in the company, but are remuneration levels reasonable? Our quick analysis into CEO remuneration would seem to indicate they are. The median total compensation for CEOs of companies similar in size to Pro Medicus, with market caps over AU$12b, is around AU$6.4m. The Pro Medicus CEO received total compensation of just AU$965k in the year to June 2024. First impressions seem to indicate a compensation policy that is favourable to shareholders. While the level of CEO compensation shouldn't be the biggest factor in how the company is viewed, modest remuneration is a positive, because it suggests that the board keeps shareholder interests in mind. It can also be a sign of good governance, more generally. Pro Medicus' earnings per share growth have been climbing higher at an appreciable rate. An added bonus for those interested is that management hold a heap of stock and the CEO pay is quite reasonable, illustrating good cash management. The sharp increase in earnings could signal good business momentum. Big growth can make big winners, so the writing on the wall tells us that Pro Medicus is worth considering carefully. Of course, profit growth is one thing but it's even better if Pro Medicus is receiving high returns on equity, since that should imply it can keep growing without much need for capital. Click on this link to see how it is faring against the average in its industry. While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in AU with promising growth potential and insider confidence. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
News.com.au
06-05-2025
- Business
- News.com.au
Health Check: Investors catch a falling knife as biotech big names bounce from lows
The big-name biotechs present short-term trading opportunities for bold investors Nothing to see here, says Sigma Healthcare Broker reckons Mach 7 shares should be worth four times more than their current value The topsy-turvy market has created some lucrative trading opportunities in our big name biotechs – but like a good joke it's a case of getting the timing right. In the case of radiology imaging giant Pro Medicus (ASX:PME), the stock has declined 7% year to date. Yet astute investors buying at the April 7 low of $176 are 35% ahead – not bad for a month's work. Those buying a year ago have more than doubled their money, despite long-term rumblings that the stock is overvalued. The experts hold mixed views. Broker Barrenjoey recently raising its recommendation on the stock to 'overweight' with a price target of $275. Macquarie Equities has a target of $257 but notes the company's recently announced contract renewals 'are clearly largely factored into the valuation'. Now in the ASX top 100, Pro Medicus is automatically included in index funds and that has kept the shares well primed. Punting on recovery Telix Pharmaceuticals (ASX:TLX) shares are about 6% off their record $31.14 on February 25. But those who bought at the April 7 low of $23.15 are 26% to the good. The stock is 22% higher year to date and almost double on a year ago. Are they good value? Depends on who you talk to. UBS and Bell Potter ascribe a $36 a share valuation, implying chunky 24% upside. Morningstar reckons the stock is worth only 19.50 – 33% less than its current level. Those who bought into CSL (ASX:CSL) at a record $336 in February 2020 have been short-changed to the tune of 24%. The stock has declined 10% year to date. But those who weighed in at $233 on April 11 are 9% to the good. Shares in ResMed (ASX:RMD) and Cochlear (ASX:COH) have also gained around 10% and 8% respectively from their mid-April lows. The lesson is that beaten-down greats usually present opportunities, but of course no-one rings the bell at the low point. Damn! Broker says Mach 7 will put on the after burners What about the challengers? Imaging minnow Mach7 Technologies (ASX:M7T) has long been viewed as a mini-version of Pro Medicus, but has yet to take off at warp speed. In fact, the shares have halved over the last year. The US focused Mach 7's quarterly results last week revealed no new contracts, but receipts gained 28% to $11.4 million. Cash flow improved to $2.6 million and contracted annual recurring revenue is at a healthy $30.8 million. Broker Morgans values the stock at $1.37 – around four times the current valuation. Investors await the new CEO Teri Thomas, who starts in July. The dynamic Thomas headed the NZ-based breast imaging house Volpara Technologies, which last year was taken over by South Korea's Lunit for around $200 million. Mach 7's $80 million market cap is backed by $25 million of cash. The board concurs the stock is undervalued, having instituted a share buyback program that has acquired $1.2 million of stock to date. Sigma chemist merger is going to script No news is good news at Sigma Healthcare (ASX:SIG), which reports that no nasties have emerged since the company officially subsumed the larger Chemist Warehouse on February 2. In a trading update, the chemist retailer and drug wholesaler says underlying earnings have risen 36% in the last nine months. That's at the same clip as Chemist Warehouse's December half earnings, up 36% to $328 million. Sigma/Chemist Warehouses has become the giant of the apothecaries with 879 franchises stores, 3500 wholesale pharmacy customers and close to $10 billion of annual revenue. The company also reports that it expects to grow retail outlets at the same clip as over the last five years: 33 per year. The company is also eyeing judicious expansion offshore, where it has 81 stores (mainly in New Zealand but also in Ireland, China and Dubai). Still, uninspired investors today sold down the stock by about 5%. Cardiex vies for local approval Australia might be a puny medical device market relative to the US, but given the Trumpian uncertainties it's still an attractive geography. Having won US Food and Drug Administration (FDA) approval of its Conneqt Pulse heart app a year ago, Cardiex (ASX:CDX) has lodged an approval application with the local Therapeutic Goods Administration (TGA). 'The world's most advanced personal arterial health monitor', Conneqt Pulse provides users with a holistic snapshot of their cardiovascular system, including central blood pressure and arterial stiffness. The app includes the Cardiology Report, a comprehensive assessment of heart health. The science is based on pulse wave analysis, which deciphers the hidden signals within each heartbeat to generate advanced vascular biomarkers. Since launching in the US in mid-January Conneqt Pulse sales are off to a good start, with 3000 units sold. By the end of June management expects a sales run rate of 900 units a month, for annual revenue of $4-5 million. Cardiex also has devices for hypertension, cardiovascular disease and other vascular health disorders. In its quarterly report last week, the company said the Trump administration's cost cutting drive had affected sales to pharmaceutical companies and research organisations in the March quarter. This is because clinical trials have been delayed or cancelled, partly because of the funding squeeze on the National Institutes of Health (which funds hundreds of studies). As for the tariff threat, the company is 'actively monitoring developments and exploring mitigation strategies, including supply diversification and regional logistics optimisation'. The sales projections for Conneqt Pulse are based on existing inventory not subject to tariffs. The TGA lodgement follows the recent finalisation of a market agreement between Cardiex and manufacturing partner, Andon. The TGA registration process is expected to take three to six months.
